Shares of Supernus Pharmaceuticals, Inc. (SUPN) have traded between $19.36 – 43.05. The next earnings date is set for Feb 25, 2020. Let’s see how its prospects are shaping up.
What does Supernus Pharmaceuticals, Inc.(SUPN) do?
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.
Looking for stocks similar to SUPN and PPBI?